This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
biotechs: Archive
Biotech Stocks Roundup: CMRX Up on JAZZ Bid, MRNA Up on Updates & More
by Zacks Equity Research
CMRX and JAZZ are in the spotlight this week following an acquisition agreement.
REGNPositive Net Change GSKPositive Net Change MRNANegative Net Change JAZZNegative Net Change
biotechnology biotechs medical pharmaceuticals
AXSM Settles Sunosi Patent Litigation With Hikma Pharmaceuticals
by Zacks Equity Research
Axsome enters into a settlement agreement with Hikma Pharmaceuticals to resolve a patent litigation related to Sunosi.
JAZZNegative Net Change RIGLPositive Net Change ANIPPositive Net Change AXSMNegative Net Change
biotechs
Editas Q4 Loss Wider Than Expected, Revenues Fall Y/Y, Stock Down
by Zacks Equity Research
EDIT stock is down following the announcement of dismal fourth-quarter 2024 results as both earnings and revenues miss estimates.
BMRNNegative Net Change GILDNegative Net Change VRTXNegative Net Change EDITNegative Net Change
biotechnology biotechs crispr gene-editing gene-therapy medical pharmaceuticals
Here's Why Moderna Stock Soared 16% on Wednesday
by Zacks Equity Research
The surge in MRNA stock comes after some SEC filings show that company insiders bought shares worth $6 million.
PFENegative Net Change MRNANegative Net Change BNTXNegative Net Change
biotechs medical pharmaceuticals vaccines
Jazz Offers to Buy Chimerix for $935M to Boost Oncology Portfolio
by Zacks Equity Research
JAZZ's acquisition of CMRX is set to add a rare high-grade brain tumor drug currently under the FDA's review. The deal is likely to be closed by June 2024.
JAZZNegative Net Change EBSPositive Net Change
biotechs medical
FATE Q4 Earnings Beat, Autoimmunity, Oncology Programs in Focus
by Zacks Equity Research
FATE Therapeutics' Q4 loss and revenues improve year over year. Its innovative pipeline is in focus.
BMRNNegative Net Change GILDNegative Net Change FATENegative Net Change
biotechnology biotechs medical pharmaceuticals
Bayer Q4 Earnings In Line, Revenues Top on Nubeqa, Kerendia Sales
by Zacks Equity Research
BAYRY's fourth-quarter earnings match expectations. Revenues top estimates, driven by the strong performance of its pharmaceutical business.
REGNPositive Net Change JNJPositive Net Change BAYRYNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
FDA Accepts RHHBY's sNDA for Gazyva in Treating Lupus Nephritis
by Zacks Equity Research
Roche's filing is based on data from a late-stage study that shows a complete renal response benefit in lupus nephritis patients who received Gazyva.
RHHBYPositive Net Change PCRXNegative Net Change ARGXPositive Net Change ETNBNegative Net Change
biotechs medical pharmaceuticals
Novo Nordisk Plunges 21% in 3 Months: Buy, Sell or Hold the Stock?
by Ahan Chakraborty
Despite the current downward trend of NVO, it is a good stock to retain in one's portfolio for long-term gains due to strong demand for its GLP-1 drugs.
NVOPositive Net Change LLYPositive Net Change AMGNPositive Net Change VKTXNegative Net Change
biotechnology biotechs medical pharmaceuticals
Bull of the Day: Pacira BioSciences (PCRX)
by David Bartosiak
Earnings moving in the right direction and a bounce off technical support sets this stop up nicely.
PCRXNegative Net Change
biotechs
Roche Gets FDA Approval for Acute Ischemic Stroke Drug for Adults
by Zacks Equity Research
RHHBY's member company, Genentech, obtains FDA nod for TNKase (tenecteplase), a thrombolytic or clot-dissolving agent, for the treatment of acute ischemic stroke in adults.
RHHBYPositive Net Change BMRNNegative Net Change GILDNegative Net Change
biotechnology biotechs medical pharmaceuticals
AXSM Gets Positive FDA Feedback for Alzheimer's Agitation Drug Filing
by Zacks Equity Research
Based on the FDA's feedback, Axsome plans to submit a supplemental NDA for AXS-05 in Alzheimer's disease agitation in third-quarter 2025.
PCRXNegative Net Change AXSMNegative Net Change ARGXPositive Net Change ETNBNegative Net Change
biotechs medical
CytomX Gears Up to Report Q4 Earnings: What Should Investors Expect?
by Zacks Equity Research
On CTMX's fourth-quarter 2024 earnings call, investors can expect updates regarding the developmental programs for its clinical-stage candidates.
AMGNPositive Net Change CTMXNegative Net Change ACIUNegative Net Change
biotechnology biotechs earnings medical oncology-screening pharmaceuticals
Acadia's Q4 Earnings Miss, Nuplazid & Daybue Drive Revenue Growth (Revised)
by Zacks Equity Research
ACAD reports mixed fourth-quarter results as earnings missed estimates while revenues beat the same, driven by year-over-year growth in Nuplazid and Daybue sales.
BMRNNegative Net Change GILDNegative Net Change FOLDNegative Net Change ACADNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Regeneron Gets Positive CHMP Opinion for Multiple Myeloma Drug
by Zacks Equity Research
The CHMP recommends conditional marketing authorization of REGN's linvoseltamab to treat adults with relapsed and refractory multiple myeloma.
REGNPositive Net Change RHHBYPositive Net Change BMRNNegative Net Change GILDNegative Net Change
biotechnology biotechs medical pharmaceuticals
KRYS Gets Positive CHMP Opinion for EU Approval of Skin Disease Drug
by Zacks Equity Research
Krystal Biotech receives positive CHMP opinion recommending the approval of Vyjuvek for treating dystrophic epidermolysis bullosa in the EU.
BMRNNegative Net Change GILDNegative Net Change FOLDNegative Net Change KRYSPositive Net Change
biotechnology biotechs medical pharmaceuticals
Apellis Q4 Loss Narrower Than Expected, Syfovre Sales Drive Revenues
by Zacks Equity Research
APLS reports better-than-expected fourth-quarter 2024 results, wherein both earnings and revenues beat estimates, driven by strong sales of Syfovre.
BMRNNegative Net Change GILDNegative Net Change FOLDNegative Net Change APLSPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Novartis Gets CHMP Opinion for Label Expansion of Fabhalta
by Zacks Equity Research
The CHMP recommends granting a marketing authorization to NVS' Fabhalta for the treatment of adults with C3 glomerulopathy, an ultra-rare, progressive kidney disease with no currently approved treatment.
NVSPositive Net Change BMRNNegative Net Change GILDNegative Net Change
biotechnology biotechs medical pharmaceuticals
ABBV Enters Obesity Bandwagon, Inks $2.2B Licensing Deal for Amylin Drug
by Zacks Equity Research
Per the terms of the deal, AbbVie will lead the development and commercialization of the obesity drug developed by Gubra.
NVOPositive Net Change LLYPositive Net Change ABBVPositive Net Change VKTXNegative Net Change
biotechs medical pharmaceuticals
Rocket Pharmaceuticals Q4 Loss Narrower Than Estimates, Pipeline in Focus
by Zacks Equity Research
RCKT incurs a narrower-than-expected fourth-quarter 2024 loss. The company provides updates on its pipeline candidates.
RIGLPositive Net Change PCRXNegative Net Change ARGXPositive Net Change RCKTNegative Net Change
biotechs earnings
NTLA's Q4 Loss Narrower Than Estimates, Revenues Increase Y/Y
by Zacks Equity Research
Intellia reports better-than-expected fourth-quarter 2024 results. The company provides updates on its pipeline candidates.
REGNPositive Net Change PCRXNegative Net Change NTLANegative Net Change ARGXPositive Net Change
biotechs earnings
Cytokinetics Q4 Loss Wider Than Expected, Aficamten in Focus
by Zacks Equity Research
CYTK reports a wider-than-expected Q4 loss as operating expenses increase. CYTK is gearing up to launch lead candidate aficamten upon a potential FDA approval.
SNYPositive Net Change BAYRYNegative Net Change CYTKPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Denali Q4 Earnings Beat Estimates, Hunter Syndrome Drug in Focus
by Zacks Equity Research
DNLI reports a narrower-than-expected loss for the fourth quarter of 2024. Denali remains on track to submit a BLA for tividenofusp alfa for the treatment of MPS II (Hunter syndrome).
SNYPositive Net Change BIIBNegative Net Change DNLINegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Kymera's Q4 Loss Wider Than Expected, Pipeline in Focus
by Zacks Equity Research
KYMR reports a wider-than-expected loss for the fourth quarter of 2024. The company expects the current cash balance to provide a runway into mid-2027.
SNYPositive Net Change BMRNNegative Net Change GILDNegative Net Change KYMRPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Pacira Q4 Earnings Top, Revenues Miss Despite Exparel Sales Growth
by Zacks Equity Research
PCRX reports mixed fourth-quarter 2024 results, wherein earnings beat estimates but revenues miss. Exparel sales witness year-over-year growth.
BMRNNegative Net Change GILDNegative Net Change FOLDNegative Net Change PCRXNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals